ICAM5 and macrophage activation syndrome: Risk factors include young age at onset, anaphylactoid reactions to tocilizumab, recurrent MAS, elevated IL-18 and in some cases elevation of other non-routine markers such as ICAM 5, eotaxin, MMP7 [16].